arXivDaily arXiv每日学术速递 周一至周五更新
arXiv 1811.06262q-bio.PE
收藏

治疗设计中进化范式的电子实现:将抗癌治疗视为达尔文过程

In Silico Implementation of Evolutionary Paradigm in Therapy Design: Towards Anti-Cancer Therapy as Darwinian Process

Branislav Brutovsky, Denis Horvath

摘要:

在这里提出的计算机研究中,我们提出了一种如何将进化原理应用到抗癌治疗设计中的方法。我们假设,而不是其正在进行的监督适应,治疗可能会被构建为一个自我维持的进化过程中的动态适应度景观建立隐式发展的癌细胞,微环境和治疗本身。为了这些目的,我们取代了统一的治疗与“治疗物种”,这是一个人口的异质性基本疗法,并提出了一种方法,如何把毒性的基本疗法到其健身的方式符合进化的因果关系。因此,不仅疗法支配不同细胞表型的演变,而且细胞的抗性也支配疗法的演变。我们说明了最低限度的特设进化模型的方法。其结果表明,耐药细胞可以通过抑制毒性较小的治疗方法,使进化偏向于毒性更大的基础治疗。由于癌症耐药性的进化原因已经被深入研究了几十年,我们将癌症作为一个特例来说明纯理论分析。

英文摘要:

In here presented in silico study we suggest a way how to implement the evolutionary principles into anti-cancer therapy design. We hypothesize that instead of its ongoing supervised adaptation, the therapy may be constructed as a self-sustaining evolutionary process in a dynamic fitness landscape established implicitly by evolving cancer cells, microenvironment and the therapy itself. For these purposes, we replace a unified therapy with the `therapy species', which is a population of heterogeneous elementary therapies, and propose a way how to turn the toxicity of the elementary therapy into its fitness in a way conforming to evolutionary causation. As a result, not only the therapies govern the evolution of different cell phenotypes, but the cells' resistances govern the evolution of the therapies as well. We illustrate the approach by the minimalistic ad hoc evolutionary model. Its results indicate that the resistant cells could bias the evolution towards more toxic elementary therapies by inhibiting the less toxic ones. As the evolutionary causation of cancer drug resistance has been intensively studied for a few decades, we refer to cancer as a special case to illustrate purely theoretical analysis.

机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。

↑